Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions

被引：1
|
作者：
Fang, Xiaosheng [1 ,2 ]
Sun, Zhongling [3 ]
Xu-Monette, Zijun Y. [1 ,4 ]
Young, Ken H. [1 ,4 ]
机构：
[1] Duke Univ, Med Ctr, Dept Pathol, Hematopathol Div, Durham, NC 27710 USA
[2] Shandong First Med Univ, Shandong Prov Hosp, Dept Hematol, Jinan, Shandong, Peoples R China
[3] Peoples Hosp Zhaoyuan City, Dept Neurol, Zhaoyuan, Shandong, Peoples R China
[4] Duke Canc Inst, Durham, NC USA
来源：
ONCOLOGIST | 2021年 / 26卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1002/onco.13605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4 / 6
页数：3
相关论文
共 50 条
  • [1] A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study
    Yu, Li, I
    Shi, Menghan
    Cai, Qingqing
    Strati, Paolo
    Hagemeister, Fredrick
    Zhai, Qiongli
    Li, Ling
    Fang, Xiaosheng
    Li, Jianyong
    Sun, Ruifang
    Zhang, Shanxiang
    Yang, Hanjin
    Wang, Zhaoming
    Qian, Wenbin
    Iwaki, Noriko
    Sato, Yasuharu
    Zhang, Lu
    Li, Jian
    Oksenhendler, Eric
    Xu-Monette, Zijun Y.
    Young, Ken H.
    ONCOLOGIST, 2020, 25 (11): : 963 - 973
  • [2] CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
    Sheila K. Pierson
    Laura Katz
    Reece Williams
    Melanie Mumau
    Michael Gonzalez
    Stacy Guzman
    Ayelet Rubenstein
    Ana B. Oromendia
    Philip Beineke
    Alexander Fosså
    Frits van Rhee
    David C. Fajgenbaum
    Nature Communications, 13
  • [3] CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
    Pierson, Sheila K.
    Katz, Laura
    Williams, Reece
    Mumau, Melanie
    Gonzalez, Michael
    Guzman, Stacy
    Rubenstein, Ayelet
    Oromendia, Ana B.
    Beineke, Philip
    Fossa, Alexander
    van Rhee, Frits
    Fajgenbaum, David C.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [4] Idiopathic multicentric Castleman's disease
    Vasilyev, V., I
    Palshina, S. G.
    Pavlovskaya, A., I
    Kokosadze, N., V
    Chaltsev, B. D.
    Shornikova, L. A.
    TERAPEVTICHESKII ARKHIV, 2020, 92 (05): : 78 - +
  • [5] Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances
    Lang, Evan
    van Rhee, Frits
    BLOOD REVIEWS, 2024, 64
  • [6] Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report
    Yujie Shi
    Jian Li
    Lu Zhang
    Annals of Hematology, 2022, 101 : 2529 - 2531
  • [7] Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report
    Shi, Yujie
    Li, Jian
    Zhang, Lu
    ANNALS OF HEMATOLOGY, 2022, 101 (11) : 2529 - 2531
  • [8] Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report
    Gao, Yu-Han
    Duan, Ming-Hui
    Li, Jian
    Zhang, Lu
    TURKISH JOURNAL OF HEMATOLOGY, 2024, 41 (01) : 61 - 63
  • [9] Dissecting idiopathic multicentric Castleman's disease
    Dupin, Nicolas
    LANCET HAEMATOLOGY, 2016, 3 (04): : E153 - E154
  • [10] Polynesian Variant Of Idiopathic Multicentric Castleman Disease
    Zhai, Shaun
    Simpson, David
    BLOOD, 2013, 122 (21)
12345